This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
News|Videos|June 17, 2025
RX Review: Expanding options and addressing gaps in RSV prevention
Fact checked by: Morgan Ebert, Executive Editor, Victoria Johnson
In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.
Advertisement
Advertisement
As the field of RSV prevention continues to grow, pediatricians face both new opportunities and new challenges. From emerging immunoprophylaxis strategies to gaps in clinician and parent education, effective RSV management requires staying ahead of a changing landscape. In this second installment of the HCP Live Network RX Review roundtable on RSV, moderator Albert Rizzo, MD, chief medical officer of the American Lung Association, continues the conversation with leading pediatric experts Tina Tan, MD, and Joanne Nazif, MD.
Related to this article
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.
AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.
Lori Handy, MD, says vaccine conversations with hesitant families should prioritize trust, follow-up, and the benefits for the individual child.
Advertisement
Advertisement